by 
Automated cell counters are medical devices used for counting and examining cells present in the human body, specifically blood, bone marrow, sperm and tissue fluid. These devices analyze cells based on their optical properties including size, shape and internal complexity, allowing clinicians to diagnose a wide range of diseases and health conditions. The global automated cell counters market relies on continued advancement in biopharmaceutical industry. New therapies pertaining to regenerative medicines, genetic engineering, tissue engineering and stem cell research are fueling demand for these devices.
The global Automated Cell Counters Market is estimated to be valued at US$ 3.75 billion in 2023 and is expected to exhibit a CAGR of 7.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Growing prevalence of infectious and chronic diseases is propelling the automated cell counters market. According to WHO, chronic diseases are estimated to account for almost three quarters of all deaths globally. In addition, rising incidence of genetic disorders is leading to increased demand for screening of genetic abnormalities during pregnancy. This is positively impacting growth of the automated cell counters market. Furthermore, technological advancements including high resolution imaging, artificial intelligence integrated cell counters are enhancing workflow efficiency and accuracy. Market players are focusing on development of multi-application devices to gain larger share.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as the automated cell counters market requires high capital investment and R&D investment. However, advancement in technologies can lower the entry barriers.
Bargaining power of buyers: The bargaining power of buyers is high as there are numerous established players offering automated cell counters at competitive prices. Buyers can negotiate on price and switch between suppliers easily.
Bargaining power of suppliers: The bargaining power of suppliers is moderate as the raw materials and components used in automated cell counters manufacturing are available from numerous suppliers globally. Suppliers do not have pricing leverage.
Threat of new substitutes: The threat of substitutes is low as automated cell counters provide accurate and reliable analysis which cannot be replicated by substitutes.
Competitive rivalry: The competitive rivalry is high owing to presence of numerous global and regional players. Players compete based on product features, reliability, pricing and innovation.
Key Takeaways
The global Automated Cell Counters market is expected to witness high growth during the forecast period of 2023 to 2030. The global Automated Cell Counters Market is estimated to be valued at US$ 3.75 billion in 2023 and is expected to exhibit a CAGR of 7.0% over the forecast period 2023 to 2030.
Regional analysis: North America is the largest market for automated cell counters owing to rising prevalence of chronic diseases like cancer which requires cell counting, growing biopharmaceutical industry and large healthcare expenditure. Asia Pacific is expected to grow at fastest pace due to increasing healthcare spending, expanding biopharma industry and growing geriatric population.
Key players: Key players operating in the automated cell counters market are Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, PerkinElmer Inc., Bio-Rad Laboratories, BD, Merck KGaA, Logos Biosystems, Corning Incorporated, and Tecan.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
